VERU - Veru Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.09
+0.01 (+0.48%)
At close: 3:43PM EDT

2.04 -0.05 (-2.39%)
After hours: 5:01PM EDT

Stock chart is not supported by your current browser
Previous Close2.08
Open2.08
Bid2.03 x 900
Ask2.12 x 1400
Day's Range2.01 - 2.11
52 Week Range0.90 - 3.00
Volume35,443
Avg. Volume133,396
Market Cap111.842M
Beta0.34
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2014-04-28
1y Target Est7.50
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Veru to Start Phase 2 Trial to Evaluate Cis-Clomiphene Citrate to Treat Hot Flashes Caused by Advanced Prostate Cancer Therapy

    Veru Inc. (VERU), a urology and oncology biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for VERU-944 (cis-clomiphene citrate).  Based on previous input by the FDA, filing the IND will allow the company to advance its proprietary drug candidate, VERU-944, directly to a Phase 2 clinical study.

  • GlobeNewswire2 months ago

    Veru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6th

    MIAMI, May 30, 2018-- Veru Inc., a urology and oncology biopharmaceutical company, today announced that the company’ s Chairman, President and Chief Executive Officer, Mitchell Steiner, M.D., will present ...

  • GlobeNewswire2 months ago

    Veru Announces Publication of Data from Three Cancer Studies as Part of the Upcoming American Society of Clinical Oncology Annual Meeting

    Veru Inc. (VERU), a urology and oncology biopharmaceutical company, today announced the publication of data from preclinical studies of VERU-111, a novel oral alpha and beta tubulin inhibitor, that showed efficacy in chemotherapy resistant tumor types. Specifically, VERU-111 reduced tumor growth in a paclitaxel sensitive and resistant triple negative breast cancer (TNBC) model, as well as ovarian cancer and pancreatic cancer models.  Three abstracts, which include data related to each of the three cancers, were published as part of the upcoming 2018 American Society of Clinical Oncology Annual Meeting in Chicago.

  • GlobeNewswire2 months ago

    Veru Announces Publication of Data on Oral VERU-111 in Prostate Cancer in Connection with the 2018 American Society of Clinical Oncology Annual Meeting

    Veru Inc. (VERU), a urology and oncology biopharmaceutical company, today announced the publication of data from preclinical studies of VERU-111, a novel oral alpha and beta tubulin inhibitor, showing potent activity in a highly resistant model of human prostate cancer.  An abstract of the data was published as part of the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. “The findings in this clinically relevant model of prostate cancer provide us with additional support and enthusiasm for evaluating VERU-111 in a Phase 1/2 clinical trial, which is scheduled to commence later this year.  This is an animal model in which few drugs have been shown to be active.  In addition, VERU 111 may be effective against other tumor types known to be sensitive to taxanes that are already FDA approved,” said Mario Eisenberger, MD, the Dale Hughes Professor of Oncology at The Johns Hopkins University.

  • GlobeNewswire2 months ago

    Veru Reports Fiscal 2018 Second-Quarter Financial Results

    --Promising Oncology Drug Data to be Presented at Upcoming American Urological Association Medical Conference; FDA Waives Drug Application Fee; BE Clinical Studies Results Anticipated for Drugs in 2018; ...

  • GlobeNewswire2 months ago

    Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 American Urological Association Meeting

    Chemotherapy prolongs survival and improves quality of life of patients with metastatic hormone sensitive and castration resistant prostate cancer. The Veru study being presented evaluated oral administration of VERU-111 compared with IV docetaxel in a paclitaxel resistant prostate cancer model.

  • GlobeNewswire2 months ago

    Veru to Report Fiscal 2018 Second-Quarter Financial Results, Host Conference Call on May 9th

    MIAMI, May 03, 2018-- Veru Inc., a urology and oncology biopharmaceutical company, today announced that on May 9, 2018, the company will report financial results for its fiscal 2018 second quarter that ...

  • ACCESSWIRE5 months ago

    Veru Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 14, 2018 / Veru Inc. (NASDAQ: VERU ) will be discussing their earnings results in their Q1 Earnings Call to be held on February 14, 2018 at 8:00 AM Eastern Time. To ...

  • ACCESSWIRE6 months ago

    Free Research Report as Veru’s Revenue Grew 3.6%

    LONDON, UK / ACCESSWIRE / January 16, 2018 / Active-Investors.com has just released a free earnings report on Veru Inc. (NASDAQ: VERU ). If you want access to this report all you need to do is sign up ...

  • Capital Cube7 months ago

    ETFs with exposure to Veru, Inc. : December 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Veru, Inc. Here are 5 ETFs with the largest exposure to VERU-US. Comparing the performance and risk of Veru, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube10 months ago

    ETFs with exposure to Veru, Inc. : September 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Veru, Inc. Here are 5 ETFs with the largest exposure to VERU-US. Comparing the performance and risk of Veru, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)